153666-19-4

Basic information

• Product Name: KETODEOXYNONULOSONIC ACID
• Synonyms: Ketodeoxynonulosonic acid (Kdn);Ketodeoxynonulosonic acidfree acid (Kdn)
• CAS NO: 153666-19-4
• Molecular Formula: C9H16O9
• Molecular Weight: 268.22
• Product Categories: Bioproducts;Sugar derivatives;Carbohydrates & Derivatives
• Mol File: 153666-19-4.mol
• Article Data: 2

Chemical Properties

• Melting Point: 26-28?C
• Boiling Point: 726.8 °C at 760 mmHg
• Flash Point: 285.4 °C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 2.18E-24mmHg at 25°C
• Storage Temp.: −20°C
• PKA: 2.34±0.70(Predicted)
• BRN: 5439887
• CAS DataBase Reference: KETODEOXYNONULOSONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: KETODEOXYNONULOSONIC ACID(153666-19-4)
• EPA Substance Registry System: KETODEOXYNONULOSONIC ACID(153666-19-4)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 153666-19-4(Hazardous Substances Data)

Usage

Description

KETODEOXYNONULOSONIC ACID (KDN) is a naturally occurring deaminated sialic acid derivative, predominantly found at the non-reducing end of sialyl chains. It is a white to off-white solid with potential anticancer properties, particularly noted for its elevated levels in human prostate cancer cells.

Uses

Used in Pharmaceutical Industry:
KETODEOXYNONULOSONIC ACID is used as a pharmaceutical compound for its potential anticancer activity. The expression is: KETODEOXYNONULOSONIC ACID is used as an anticancer agent for its potential to target and treat cancer cells, particularly in prostate cancer.
Used in Research and Development:
KETODEOXYNONULOSONIC ACID is used as a research compound for studying the role of sialic acid derivatives in cancer cell biology and their potential applications in cancer treatment. The expression is: KETODEOXYNONULOSONIC ACID is used as a research tool for understanding the mechanisms behind its elevated levels in prostate cancer cells and its potential therapeutic effects.
Used in Drug Development:
KETODEOXYNONULOSONIC ACID is used as a starting material or intermediate in the development of novel anticancer drugs. The expression is: KETODEOXYNONULOSONIC ACID is used as a chemical building block for creating new drugs that target cancer cells, leveraging its inherent anticancer properties.

InChI:InChI=1/C9H16O9/c10-2-4(12)6(14)7-5(13)3(11)1-9(17,18-7)8(15)16/h3-7,10-14,17H,1-2H2,(H,15,16)/p-1/t3-,4+,5+,6-,7-,9-/m0/s1

Upstream product

• 7757-38-2 2,3,5,6-di-O-isopropylidene-D-mannofuranose 
• 1346258-05-6 1,2,3-trideoxy-5,6;8,9-di-O-isopropylidene-D-manno-non-1-yno-4-ulofuranose 
• 148616-97-1 1,2,3-trideoxy-5,6:8,9-di-O-isopropylidene-D-glycero-D-galacto-1-yno-nonitol 
• 1346258-07-8 1-bromo-1,2,3-trideoxy-5,6:8,9-di-O-isopropylidene-D-glycero-D-galacto-1-yno-nonitol 
• 1346258-08-9 1-bromo-1,2,3-trideoxy-D-glycero-D-galacto-1-yno-nonitol 
• 64-19-7 acetic acid 
• 7306-64-1 2,3,5,6-di-O-isopropylidene-D-mannono-1,4-lactone 
• 530-26-7 D-Mannose 
• 113-24-6 sodium pyruvate 

Relevant articles and documents

Diastereoselective One-Step Synthesis of 2-Keto-3-deoxy-d- glycero-d-galacto-nononic acid (KDN) Analogues as Templates for the Development of Influenza Drugs

Novel sialic acid scaffolds have great significance in the development of influenza neuraminidase inhibitors. Here the enzymatic synthesis of a wide range of 2-keto-3-deoxy-d-glycero-d-galacto-nononic acid (KDN) analogues via aldol addition of pyruvate to d-mannose, d-glucose, d-galactose, 2-deoxy-d-glucose, d-arabinose, l-arabinose and l-rhamnose using a previously unstudied N-acetylneuraminic acid (Neu5Ac) aldolase derived from the bacterium Dyadobacter fermentas is exemplified. Several of the synthesized KDN analogues showed comparable or better inhibitory activity than unstudied Neu5Ac against the mutated influenza neuraminidases (A/California/04/2009 and A/Anhui/1/2005), which both show resistance to Neu5Ac-based neuraminidase inhibitors, demonstrating that these compounds are promising templates for the development of anti-influenza drugs. (Figure presented.).